Cargando…

Prognostic Impact of (18)FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer

BACKGROUND: This study prospectively evaluated the yield of fluorodeoxyglucose positron emission tomography/computed tomography ((18)FDG-PET-CT) in patients with clinical stages II and III breast cancer and the impact of PET-CT results on prognosis. METHODS: In the course of 71 months, 254 consecuti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Groheux, David, Hindié, Elif, Delord, Marc, Giacchetti, Sylvie, Hamy, Anne-sophie, de Bazelaire, Cédric, de Roquancourt, Anne, Vercellino, Laetitia, Toubert, Marie-Elisabeth, Merlet, Pascal, Espié, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525816/ https://www.ncbi.nlm.nih.gov/pubmed/23243198 http://dx.doi.org/10.1093/jnci/djs451

Ejemplares similares

HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment
por: Groheux, D, et al.
Publicado: (2013)

Breast cancer: initial workup and staging with FDG PET/CT
por: Groheux, David, et al.
Publicado: (2021)

(18)FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis
por: Groheux, David, et al.
Publicado: (2017)

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
por: Giacchetti, Sylvie, et al.
Publicado: (2022)

Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer
por: Bousquet, Guilhem, et al.
Publicado: (2017)

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15
por: Lehmann-Che, Jacqueline, et al.
Publicado: (2013)

Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC
por: Campedel, Luca, et al.
Publicado: (2020)

(18)FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients
por: de Cremoux, Patricia, et al.
Publicado: (2018)

Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma
por: Pesqué, Louise, et al.
Publicado: (2022)

18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors
por: Rivas, Alexia, et al.
Publicado: (2022)

Accuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study
por: de Bazelaire, Cédric, et al.
Publicado: (2011)

Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma
por: Bousquet, Guilhem, et al.
Publicado: (2014)

The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors
por: Hindié, Elif
Publicado: (2017)

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen
por: Giacchetti, S, et al.
Publicado: (2014)

(18)F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients
por: Girum, Kibrom B., et al.
Publicado: (2022)

A massive open online course to teach undergraduate medical students in oncology: keys of success
por: Hamdan, Diaddin, et al.
Publicado: (2022)

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches
por: Lehmann-Che, J, et al.
Publicado: (2011)

Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial
por: Mesguich, Charles, et al.
Publicado: (2020)

Prospective Comparison of 18-FDG PET/CT and Whole-Body MRI with Diffusion-Weighted Imaging in the Evaluation of Treatment Response of Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant
por: Mesguich, Charles, et al.
Publicado: (2021)

Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma
por: Vercellino, Laetitia, et al.
Publicado: (2022)

Choline PET/CT in Multiple Myeloma
por: Mesguich, Charles, et al.
Publicado: (2020)

Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist (68)Ga-RM2 and (18)F-FDG in breast cancer samples
por: Morgat, Clément, et al.
Publicado: (2019)

FDG-PET/CT based response-adapted treatment
por: de Geus-Oei, Lioe-Fee, et al.
Publicado: (2012)

New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT
por: Cottereau, Anne-Ségolène, et al.
Publicado: (2021)

FDG-PET in colorectal cancer
por: de Geus-Oei, Lioe-Fee, et al.
Publicado: (2006)

Deep-Learning (18)F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma
por: Capobianco, Nicolò, et al.
Publicado: (2021)

Lymphomatoid Granulomatosis: CT and FDG-PET Findings
por: Chung, Jonathan H., et al.
Publicado: (2011)

FDG-PET in lymphoma
por: Meignan, Michel
Publicado: (2014)

PET-FDG: Impetus
por: Nanni, Cristina
Publicado: (2020)

Predictive and prognostic value of FDG-PET
por: de Geus-Oei, Lioe-Fee, et al.
Publicado: (2008)

FDG-PET and PET/CT - Part II
por: Takalkar, Amol M, et al.
Publicado: (2008)

Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen
por: Bertheau, Philippe, et al.
Publicado: (2007)

FDG-PET of Takayasu’s Arteritis
por: Shikino, Kiyoshi, et al.
Publicado: (2014)

FDG-PET/CT in lymphoma
por: D'souza, Maria M, et al.
Publicado: (2013)

FDG-PET and colon cancer
por: Miles, Ken
Publicado: (2015)

F-18 FDG PET brain imaging in symptomatic arthroprosthetic cobaltism
por: Bridges, Robert L., et al.
Publicado: (2019)

Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT
por: Park, Jong Sun, et al.
Publicado: (2011)

FDG uptake heterogeneity in FIGO IIb cervical carcinoma does not predict pelvic lymph node involvement
por: Brooks, Frank J, et al.
Publicado: (2013)

[(18)F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives
por: Kanoun, Salim, et al.
Publicado: (2018)

FDG PET/CT in Initial Staging of Adult Soft-Tissue Sarcoma
por: Roberge, David, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3d8tsmq481s47ir12ab886kqcl